Skip to main content
. Author manuscript; available in PMC: 2024 May 8.
Published in final edited form as: Eur J Endocrinol. 2023 Jul 20;189(1):123–131. doi: 10.1093/ejendo/lvad085

Figure 5.

Figure 5.

Individual evolution of height in the study group. The iPPSD2/PHP1A participants treated with rhGH are depicted using circles: in blue for the time points before the therapy and in red for the measurements collected under active treatment. The height measurements for the iPPSD2/PHP1A controls are depicted using blue triangles. The gray interrupted lines indicate −2 and +2 SDS, representing the normal range for height.